Credit Suisse’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $62.9M | Sell |
291,725
-26,696
| -8% | -$6.25M | 0.06% | 311 |
|
|
2023
Q4 | $82.4M | Sell |
318,421
-30,290
| -9% | -$7.44M | 0.08% | 247 |
|
|
2023
Q3 | $89.6M | Sell |
348,711
-2,685
| -0.8% | -$718K | 0.09% | 218 |
|
|
2023
Q2 | $100M | Buy |
351,396
+2,303
| +0.7% | +$686K | 0.1% | 204 |
|
|
2023
Q1 | $97.1M | Sell |
349,093
-11,263
| -3% | -$3.12M | 0.1% | 207 |
|
|
2022
Q4 | $99.8M | Buy |
360,356
+61,320
| +21% | +$17.3M | 0.11% | 201 |
|
|
2022
Q3 | $79.8M | Sell |
299,036
-32,765
| -10% | -$6.96M | 0.09% | 236 |
|
|
2022
Q2 | $67.7M | Sell |
331,801
-13,389
| -4% | -$2.74M | 0.07% | 293 |
|
|
2022
Q1 | $72.7M | Buy |
345,190
+46,761
| +16% | +$10.2M | 0.06% | 332 |
|
|
2021
Q4 | $71.6M | Buy |
298,429
+6,454
| +2% | +$1.66M | 0.04% | 488 |
|
|
2021
Q3 | $82.6M | Buy |
291,975
+20,909
| +8% | +$6.85M | 0.05% | 434 |
|
|
2021
Q2 | $93.9M | Sell |
271,066
-8,392
| -3% | -$2.54M | 0.05% | 407 |
|
|
2021
Q1 | $78.2M | Sell |
279,458
-100,801
| -27% | -$27.2M | 0.04% | 514 |
|
|
2020
Q4 | $93.1M | Sell |
380,259
-14,360
| -4% | -$3.7M | 0.05% | 442 |
|
|
2020
Q3 | $112M | Sell |
394,619
-84,792
| -18% | -$23.6M | 0.07% | 312 |
|
|
2020
Q2 | $128M | Buy |
479,411
+15,124
| +3% | +$4.55M | 0.09% | 219 |
|
|
2020
Q1 | $147M | Sell |
464,287
-16,581
| -3% | -$5.03M | 0.13% | 133 |
|
|
2019
Q4 | $143M | Sell |
480,868
-27,354
| -5% | -$7.59M | 0.1% | 182 |
|
|
2019
Q3 | $118M | Sell |
508,222
-30,736
| -6% | -$7.16M | 0.1% | 188 |
|
|
2019
Q2 | $126M | Buy |
538,958
+8,187
| +2% | +$1.89M | 0.11% | 166 |
|
|
2019
Q1 | $125M | Buy |
530,771
+90,627
| +21% | +$28.5M | 0.11% | 159 |
|
|
2018
Q4 | $132M | Buy |
440,144
+20,151
| +5% | +$6.43M | 0.14% | 137 |
|
|
2018
Q3 | $148M | Sell |
419,993
-2,268
| -0.5% | -$781K | 0.13% | 139 |
|
|
2018
Q2 | $123M | Sell |
422,261
-52,085
| -11% | -$14.6M | 0.12% | 149 |
|
|
2018
Q1 | $130M | Buy |
474,346
+21,908
| +5% | +$6.8M | 0.12% | 152 |
|
|
2017
Q4 | $144M | Sell |
452,438
-29,625
| -6% | -$9.5M | 0.13% | 140 |
|
|
2017
Q3 | $151M | Sell |
482,063
-16,743
| -3% | -$4.96M | 0.15% | 129 |
|
|
2017
Q2 | $135M | Sell |
498,806
-96,325
| -16% | -$25.5M | 0.13% | 139 |
|
|
2017
Q1 | $163M | Buy |
595,131
+65,230
| +12% | +$18.4M | 0.15% | 129 |
|
|
2016
Q4 | $150M | Sell |
529,901
-210,344
| -28% | -$62.4M | 0.15% | 124 |
|
|
2016
Q3 | $232M | Buy |
740,245
+66,193
| +10% | +$19.6M | 0.22% | 82 |
|
|
2016
Q2 | $163M | Buy |
674,052
+23,394
| +4% | +$6.17M | 0.18% | 104 |
|
|
2016
Q1 | $169M | Buy |
650,658
+14,473
| +2% | +$3.82M | 0.2% | 96 |
|
|
2015
Q4 | $195M | Sell |
636,185
-1,877
| -0.3% | -$539K | 0.22% | 91 |
|
|
2015
Q3 | $186M | Sell |
638,062
-62,270
| -9% | -$20.6M | 0.22% | 88 |
|
|
2015
Q2 | $283M | Buy |
700,332
+43,601
| +7% | +$17.5M | 0.28% | 69 |
|
|
2015
Q1 | $277M | Sell |
656,731
-57,434
| -8% | -$22.6M | 0.28% | 71 |
|
|
2014
Q4 | $242M | Buy |
714,165
+64,607
| +10% | +$20.9M | 0.22% | 89 |
|
|
2014
Q3 | $215M | Buy |
649,558
+96,020
| +17% | +$31.7M | 0.18% | 105 |
|
|
2014
Q2 | $175M | Buy |
553,538
+11,942
| +2% | +$3.59M | 0.14% | 133 |
|
|
2014
Q1 | $166M | Sell |
541,596
-101,826
| -16% | -$32.3M | 0.16% | 110 |
|
|
2013
Q4 | $180M | Buy |
643,422
+111,634
| +21% | +$28.9M | 0.16% | 105 |
|
|
2013
Q3 | $128M | Sell |
531,788
-126,836
| -19% | -$28.4M | 0.13% | 136 |
|
|
2013
Q2 | $142M | Buy |
+658,624
| New | +$141M | 0.14% | 108 |
|
Other funds holding BIIB
Credit Suisse's BIIB Position: Q1 2024 in Review
Credit Suisse reduced its Biogen (BIIB) stake by 8.4% in Q1 2024, selling an estimated $6.25M and leaving 291,725 shares worth $62.9M. The position accounts for 0.06% of the portfolio, ranked #311.
Credit Suisse first reported a position in BIIB in Q2 2013 and has held it in 44 quarters since. The position peaked at $283M in Q2 2015. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.
- Credit Suisse held 291,725 shares of Biogen worth $62.9M as of Q1 2024.
- Credit Suisse sold 26,696 Biogen shares in Q1 2024, an estimated $6.25M.
- Biogen made up 0.06% of Credit Suisse's portfolio in Q1 2024, its #311 holding.
- Credit Suisse first reported a position in Biogen in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Biogen position peaked at $283M in Q2 2015.
- 954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.